EP2167961A4 - Bêta-2-microglobuline et protéine c réactive (crp) en tant que biomarqueurs pour une maladie artérielle périphérique - Google Patents

Bêta-2-microglobuline et protéine c réactive (crp) en tant que biomarqueurs pour une maladie artérielle périphérique

Info

Publication number
EP2167961A4
EP2167961A4 EP08772081A EP08772081A EP2167961A4 EP 2167961 A4 EP2167961 A4 EP 2167961A4 EP 08772081 A EP08772081 A EP 08772081A EP 08772081 A EP08772081 A EP 08772081A EP 2167961 A4 EP2167961 A4 EP 2167961A4
Authority
EP
European Patent Office
Prior art keywords
beta2
microglobulin
crp
biomarkers
artery disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08772081A
Other languages
German (de)
English (en)
Other versions
EP2167961A1 (fr
Inventor
John P Cooke
Andrew Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of EP2167961A1 publication Critical patent/EP2167961A1/fr
Publication of EP2167961A4 publication Critical patent/EP2167961A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP08772081A 2007-06-27 2008-06-26 Bêta-2-microglobuline et protéine c réactive (crp) en tant que biomarqueurs pour une maladie artérielle périphérique Withdrawn EP2167961A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94668107P 2007-06-27 2007-06-27
PCT/US2008/068430 WO2009003142A1 (fr) 2007-06-27 2008-06-26 Bêta-2-microglobuline et protéine c réactive (crp) en tant que biomarqueurs pour une maladie artérielle périphérique

Publications (2)

Publication Number Publication Date
EP2167961A1 EP2167961A1 (fr) 2010-03-31
EP2167961A4 true EP2167961A4 (fr) 2010-07-21

Family

ID=40186040

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08772081A Withdrawn EP2167961A4 (fr) 2007-06-27 2008-06-26 Bêta-2-microglobuline et protéine c réactive (crp) en tant que biomarqueurs pour une maladie artérielle périphérique

Country Status (3)

Country Link
US (1) US8227201B2 (fr)
EP (1) EP2167961A4 (fr)
WO (1) WO2009003142A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5357746B2 (ja) 2006-03-11 2013-12-04 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 末梢性の動脈疾患のためのバイオマーカーとしてのβ−２ミクログロブリン
PT2240781T (pt) 2008-01-18 2018-03-28 Harvard College Métodos de deteção de assinaturas de doença ou afeções em fluidos corporais
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP2282769A4 (fr) * 2008-04-29 2012-04-25 Abbott Lab Immunoglobulines à double domaine variable et utilisations
KR20110016959A (ko) * 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
PE20100092A1 (es) * 2008-06-03 2010-03-12 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
MX2010014574A (es) * 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
MX2011011670A (es) * 2009-05-01 2011-11-18 Abbott Lab Inmunoglobulinas de dominio variable dual y usos de las mismas.
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8586714B2 (en) * 2009-09-01 2013-11-19 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
CA2775959A1 (fr) * 2009-10-15 2011-04-21 Abbott Laboratories Immunoglobulines a deux domaines variables et utilisations afferentes
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
GB201004442D0 (en) * 2010-03-17 2010-05-05 Binding Site Group The Biomarker
GB201012049D0 (en) 2010-07-19 2010-09-01 Binding Site Group The Ltd Competition assay
CA2806291C (fr) 2010-07-23 2023-08-29 President And Fellows Of Harvard College Procedes de detection de signatures de maladies ou pathologies dans des liquides biologiques
US20130203624A1 (en) 2010-07-23 2013-08-08 President And Fellows Of Harvard College Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions
KR20130041962A (ko) 2010-07-23 2013-04-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 식작용 세포를 사용하여 질환 또는 상태를 검출하는 방법
WO2012012709A2 (fr) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Méthodes de détection de maladies ou de pathologies cardiovasculaires
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
AU2011285852B2 (en) 2010-08-03 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CN103260639A (zh) 2010-08-26 2013-08-21 Abbvie公司 双重可变结构域免疫球蛋白及其用途
EP2797955A2 (fr) 2011-12-30 2014-11-05 AbbVie Inc. Immunoglobulines à double domaine variable contre contre il-13 et/ou il-17
EP2861765B1 (fr) 2012-06-15 2019-01-23 Progenity, Inc. Procédés de détection de maladies ou d'états
BR112014031414A2 (pt) 2012-06-15 2017-06-27 Stylli Harry métodos de detectar doenças ou condições utilizando células doentes circulantes
MY171664A (en) 2012-11-01 2019-10-22 Abbvie Inc Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof
US11585814B2 (en) 2013-03-09 2023-02-21 Immunis.Ai, Inc. Methods of detecting prostate cancer
US10494675B2 (en) 2013-03-09 2019-12-03 Cell Mdx, Llc Methods of detecting cancer
EP2970459A2 (fr) 2013-03-15 2016-01-20 AbbVie Inc. Protéines de liaison spécifiques à domaines variables doubles dirigées contre il -1beta et il -17
US10895571B2 (en) 2013-06-06 2021-01-19 Siemens Healthineers Nederland B.V. Reagents, methods and devices to prevent aggregation in particle based tests for the detection of multimeric target molecules
AU2015314813B2 (en) 2014-09-11 2022-02-24 Immunis.Ai, Inc. Methods of detecting prostate cancer
WO2016094881A2 (fr) 2014-12-11 2016-06-16 Abbvie Inc. Protéines de liaison à lrp-8
WO2016178121A1 (fr) 2015-05-01 2016-11-10 The University Of British Columbia Biomarqueurs pour la détection du rejet aigu de greffe du cœur
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
WO2018129056A1 (fr) * 2017-01-04 2018-07-12 The Research Foundation For The State University Of New York Dispositif de détection de biomarqueur
JP7372251B2 (ja) * 2017-11-02 2023-10-31 プリベンシオ，インコーポレイテッド 末梢動脈疾患、大動脈弁狭窄症についての診断および予後の方法、ならびにアウトカム
AU2022388722A1 (en) * 2021-11-09 2024-05-23 Truebinding, Inc. Methods of treating or inhibiting cardiovascular diseases
CN117491617B (zh) * 2023-11-01 2024-05-03 河北康卫仕医疗科技有限公司 一种对血常规分析同时测量crp的分析设备

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007106466A2 (fr) * 2006-03-11 2007-09-20 The Board Of Trustees Of The Leland Stanford Junior University Bêta-2 microglobuline utilisée comme biomarqueur pour des maladies artérielles périphériques
WO2008057966A2 (fr) * 2006-11-01 2008-05-15 Vermillion, Inc. Panel de biomarqueurs de maladie d'artères périphériques

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030149997A1 (en) * 1999-02-19 2003-08-07 Hageman Gregory S. Diagnostics and therapeutics for arterial wall disruptive disorders
WO2001002866A1 (fr) 1999-02-19 2001-01-11 University Of Iowa Research Foundation Procedes de diagnostic et de therapie pour les maladies affectant la paroi arterielle
JP2005053728A (ja) 2003-08-01 2005-03-03 Dsl Japan Co Ltd 高吸油性および高い構造性を有する非晶質シリカ粒子
JP4948399B2 (ja) * 2004-06-03 2012-06-06 ヴァーミリオン インコーポレイテッド 末梢動脈疾患についてのバイオマーカー
EP1615036B1 (fr) 2004-07-07 2007-09-19 F.Hoffmann-La Roche Ag Combinaison de marqueurs pour le diabète de type 1 et 2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007106466A2 (fr) * 2006-03-11 2007-09-20 The Board Of Trustees Of The Leland Stanford Junior University Bêta-2 microglobuline utilisée comme biomarqueur pour des maladies artérielles périphériques
WO2008057966A2 (fr) * 2006-11-01 2008-05-15 Vermillion, Inc. Panel de biomarqueurs de maladie d'artères périphériques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2009003142A1 *
WILSON ANDREW M ET AL: "beta 2-microglobulin as a biomarker in peripheral arterial disease - Proteomic profiling and clinical studies", CIRCULATION, vol. 116, no. 12, September 2007 (2007-09-01), pages 1396 - 1403, XP002583808, ISSN: 0009-7322 *

Also Published As

Publication number Publication date
US20090042214A1 (en) 2009-02-12
WO2009003142A1 (fr) 2008-12-31
US8227201B2 (en) 2012-07-24
EP2167961A1 (fr) 2010-03-31

Similar Documents

Publication Publication Date Title
EP2167961A4 (fr) Bêta-2-microglobuline et protéine c réactive (crp) en tant que biomarqueurs pour une maladie artérielle périphérique
GB0715171D0 (en) Sample processor
EP2083274A4 (fr) Appareil d'analyse du sang
PL1968711T3 (pl) Lepkosprężysty żel do zastosowania dermatologicznego
EP1961382A4 (fr) Appareil pour analyses sanguines
ZA201000095B (en) Multiple analysis of blood samples
EP2158326A4 (fr) Marqueurs biologiques pour le diagnostic d'une maladie auto-immune
GB0706820D0 (en) Blood grouop antibody screening
EP2115664A4 (fr) Analyse quantitative sur des caractéristiques cutanées
EP1997434A4 (fr) Dispositif d'examen sanguin
GB0504767D0 (en) Lipocalin protein
EP2168481A4 (fr) Dispositif d'analyse de sang
EP1997432A4 (fr) Dispositif de test sanguin
EP2346387B8 (fr) Analyse de sang
EP2001362A4 (fr) Tomographie opto-acoustique quantitative à contraste amélioré
WO2008016652A9 (fr) Imagerie de vaisseaux sanguins et ses utilisations
WO2010141469A9 (fr) Biomarqueurs de protéine et cibles thérapeutiques pour maladies autoimmunes et alloimmunes
IL205353A0 (en) Diagnostic biomarkers of diabetes
EP2035830A4 (fr) Complexe proteine/peptide lie a l'albumine en tant que biomarqueur pour une maladie
PL2135075T3 (pl) Oznaczenie pełnej krwi
EP2352035A4 (fr) Micropuce et appareil d analyse
EP1983892A4 (fr) Mesure de la pression sanguine
EP2123222A4 (fr) Dispositif de contrôle du sang
GB0815576D0 (en) Analysis of glycated proteins
EP2109688A4 (fr) Proteine de liaison a la galectine-3 en tant que biomarqueur de maladie cardiovasculaire

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100104

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20100601BHEP

Ipc: G01N 33/53 20060101AFI20090123BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100617

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1142957

Country of ref document: HK

17Q First examination report despatched

Effective date: 20110308

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20111213

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1142957

Country of ref document: HK